Benzyl salicylate


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:12686300IVTH0.000000001 - 0.0001 M 0.00001 MCancer phenotypeEndocrine-mediated cancer
PMID:19338011IVTH0.0000001 - 0.0001 M 0.00005 MCancer phenotypeEndocrine-mediated cancer
PMID:22197706IVR100 mg/kg/day 100 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR33.3 mg/kg/day 33.3 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR300 mg/kg/day 300 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations
IVR11.1 mg/kg/day 11.1 mg/kg/dayIncreased uterine weightsReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.